|
NUP155 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.83249999619051E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.0016999996143E-07 |
| Normal-vs-Stage2 |
1.076060E-03 |
| Normal-vs-Stage3 |
1.1550999999832E-06 |
| Normal-vs-Stage4 |
1.056999999971E-06 |
| Stage1-vs-Stage2 |
5.384400E-01 |
| Stage1-vs-Stage3 |
7.056400E-01 |
| Stage1-vs-Stage4 |
3.152600E-01 |
| Stage2-vs-Stage3 |
4.375400E-01 |
| Stage2-vs-Stage4 |
2.190400E-01 |
| Stage3-vs-Stage4 |
5.266800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.21589999869354E-08 |
| Normal-vs-AfricanAmerican |
9.020700E-03 |
| Normal-vs-Asian |
3.89649999998909E-06 |
| Caucasian-vs-AfricanAmerican |
4.239200E-01 |
| Caucasian-vs-Asian |
5.314800E-01 |
| AfricanAmerican-vs-Asian |
2.343200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.38070000169577E-08 |
| Normal-vs-Female |
1.17729999971061E-07 |
| Male-vs-Female |
2.497000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.34629999995573E-06 |
| Normal-vs-Age(41-60Yrs) |
1.29830000084041E-08 |
| Normal-vs-Age(61-80Yrs) |
1.53840000000072E-05 |
| Normal-vs-Age(81-100Yrs) |
5.439900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.991580E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.006200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.840800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.246200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.728600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.442200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.423200E-01 |
| Classical-VS-Follicular |
4.332200E-02 |
| Classical-VS-Other |
6.619800E-02 |
| Classical-VS-Normal |
1.2824999999772E-06 |
| Tall-VS-Follicular |
8.955800E-01 |
| Tall-VS-Other |
2.504200E-01 |
| Tall-VS-Normal |
1.153440E-04 |
| Follicular-VS-Other |
2.938600E-01 |
| Follicular-VS-Normal |
3.20099999950862E-07 |
| Other-VS-Normal |
8.047000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.63940000253282E-08 |
| Normal-vs-N1 |
8.40610000052422E-07 |
| N0-vs-N1 |
3.596200E-01 |
|
|
